Optionale Produktanalyse
Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
McKesson Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $87.2B | |
|---|---|---|
| Revenue (ttm) | 411B | |
| Net income (ttm) | 4.6B | |
| EPS (ttm) | $37.5 | |
| Shares out | 116.6M | |
| P/E (trailing) | 25.6x | |
| P/E (forward) | 14.4x | |
| Dividend | $3.76 (0.39%) | |
| Volume | 623,059 | |
| Beta | 0.30 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | Trend |
| Revenue | $263.97B | $276.71B | $308.95B | $359.05B | +10.8% |
| Gross profit | $13.13B | $12.36B | $12.83B | $13.32B | +0.5% |
| Operating income | $2.11B | $4.88B | $4.04B | $4.62B | +30.0% |
| Net income | $1.11B | $3.56B | $3.00B | $3.30B | +43.5% |
| EPS (diluted) | $7.23 | $25.03 | $22.39 | $25.72 | +52.7% |
| EBITDA | $2.87B | $5.49B | $4.68B | $5.26B | +22.4% |
| R&D | — | — | — | — | — |
| SG&A | $10.54B | $7.78B | $8.66B | $8.51B | -6.9% |
Recent company headlines from major financial publishers.
Expansion into higher-margin specialty and oncology services successfully transforms the revenue mix. Operating margins expand, and steady cash flows fuel aggressive buybacks, pushing value to the $1,308 high.
McKesson maintains its dominant oligopoly position. Predictable cash flows support steady share repurchases and dividends. Forward earnings trajectory bypasses WACC anomalies to deliver a $1,016 intrinsic value.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 3.5% | $1,168 | $1,558 | $1,561 | $1,561 | $1,561 |
| 4.1% | $892 | $1,102 | $1,442 | $1,561 | $1,561 |
| 5.1% | $645 | $749 | $892 | $1,102 | $1,442 |
| 6.1% | $506 | $567 | $645 | $749 | $892 |
| 7.1% | $491 | $491 | $506 | $567 | $645 |
Upcoming earnings date and setup when available.
Das Rating, das die veröffentlichte Research-Ausgabe des jeweiligen Monats trug. Ein Rating vergleicht den Kurs zum Analysezeitpunkt mit dem Fair Value; es ist kein Nachweis, ob die Einschätzung zutraf.
| Jahr | Jan | Feb | Mär | Apr | Mai | Jun | Jul | Aug | Sep | Okt | Nov | Dez |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |